Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34686
Full metadata record
DC FieldValueLanguage
dc.contributor.authorQin, Simon Xiwen-
dc.contributor.authorCheng, Franco Wing Tak-
dc.contributor.authorKwok, Wang Chun-
dc.contributor.authorFung, Lydia W Y-
dc.contributor.authorMa, Tian Tian-
dc.contributor.authorYiu, Hei Hang Edmund-
dc.contributor.authorBloom, Chloe-
dc.contributor.authorMcDonald, Christine F-
dc.contributor.authorCheung, Ching-Lung-
dc.contributor.authorLai, Francisco Tsz Tsun-
dc.contributor.authorChui, Celine Sze Ling-
dc.contributor.authorLi, Xue-
dc.contributor.authorWong, Carlos King Ho-
dc.contributor.authorWan, Eric Yuk Fai-
dc.contributor.authorWong, Ian Chi Kei-
dc.contributor.authorChan, Esther Wai Yin-
dc.date2023-
dc.date.accessioned2024-01-02T02:01:51Z-
dc.date.available2024-01-02T02:01:51Z-
dc.date.issued2024-02-
dc.identifier.citationDrug Safety 2024-02; 47(2)en_US
dc.identifier.issn1179-1942-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34686-
dc.description.abstractEffectiveness and respiratory adverse events following coronavirus disease-2019 (COVID-19) vaccines have not been well investigated in Chinese patients with chronic obstructive pulmonary disease (COPD) and asthma. Using electronic health care records in Hong Kong, we included adults with COPD or asthma or both and hospitalised for severe respiratory exacerbation in a self-controlled case series (SCCS) study between 23/02/2021 and 30/11/2022. Conditional Poisson regression models were used to estimate the incidence of outcomes within exposure periods (28 days after each dose) compared with baseline periods. Cox proportional hazard models evaluated vaccine effectiveness (VE) against COVID-related mortality, hospitalisation, and severe complications, including admission to intensive care units or ventilatory support. The VE assessment was based on vaccine types and the number of doses. In the SCCS, 343 CoronaVac recipients and 212 BNT162b2 recipients were included. No increased risk of outcomes was observed within the exposure periods. In the cohort study, 108,423 and 83,323 patients received ≥ 2 doses of CoronaVac and BNT162b2, respectively. The VE (95% CI) against COVID-related mortality, hospitalisation, and severe complications after two-dose CoronaVac was 77% (74-80%), 18% (6-23%), and 29% (12-43%), respectively, while for the two-dose regimen of BNT162b2, it was 92% (91-94%), 33% (30-37%), and 57% (45-66%), respectively. Higher VE against COVID-related mortality, hospitalisation, and severe complications was found for the three-dose regimen of CoronaVac (94%, 40%, and 71%) and BNT162b2 (98%, 65%, and 83%). Administering a fourth dose of either vaccine showed additional reductions in COVID-related outcomes. Among people with COPD and asthma, the COVID-19 vaccines CoronaVac and BNT162b2 did not increase severe exacerbations and achieved moderate-to-high effectiveness against COVID-related outcomes. COVID-19 vaccination remains essential and should be encouraged to protect this vulnerable population in future epidemic waves.en_US
dc.language.isoeng-
dc.titleEffectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleDrug Safetyen_US
dc.identifier.affiliationCentre for Safe Medicine Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L2-57, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China.;Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Sha Tin, Hong Kong SAR, China.;School of Population and Global Health, The University of Western Australia, Perth, Australia.en_US
dc.identifier.affiliationCentre for Safe Medicine Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L2-57, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China.en_US
dc.identifier.affiliationDepartment of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.en_US
dc.identifier.affiliationFaculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK.en_US
dc.identifier.affiliationRespiratory and Sleep Medicineen_US
dc.identifier.affiliationLaboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Sha Tin, Hong Kong SAR, China.;School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.;School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.en_US
dc.identifier.doi10.1007/s40264-023-01364-7en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-7602-9470en_US
dc.identifier.pubmedid38085500-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptRespiratory and Sleep Medicine-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Jun 12, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.